Study of BHV-4157 in Alzheimer's DiseaseResearch Question:
Does the drug Riluzole (BHV-4157) help patients with Alzheimer's Disease?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect
AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg,
placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also
screening period of up to 42 days; and a 4-week post-treatment observation period.
Study Contact InformationStudy Coordinator: Nancy Kowalski
Phone: (585) 760-6569
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search